Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume
The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...
AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...
Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...
Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...
Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...
Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...
CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...
Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...
Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...
HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...
Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...
Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...
Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...